X4 PHARMACEUTICALS, INC Accrued Royalties, Current
X4 PHARMACEUTICALS, INC (XFOR) had Accrued Royalties, Current of $3.09 million as of 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Notes › Payables and Accruals › Accrued Liabilities, Current
us-gaap:AccruedRoyaltiesCurrent · last filed 2025-03-26
- 2024-12-31: Accrued Royalties, Current $3.09M.
- 2023-12-31: Accrued Royalties, Current $0.00.
| Period end | Accrued Royalties, Current |
|---|---|
| 2024-12-31 | $3.09M 10-K · filed 2025-03-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |